Recombinant Human PRL2/PTP4A2 Protein

重组人 PRL2/PTP4A2蛋白 | 重组人酪氨酸磷酸酶4A2蛋白

EC 3.1.3.48 | HH13 | HH7-2 | HU-PP-1 | HU-PP-1HH13 | OV-1 | OV-1PTP4A | PRL2 | PRL-2 | PRL-2HH7-2 | PRL2protein tyrosine phosphatase IVA | protein tyrosine phosphatase IVA2 | protein tyrosine phosphatase type IVA 2 | protein tyrosine phosphatase type IVA

rp183697-10μg

10μg

无载体

≥95%(SDS-PAGE)

PRL-2 (Protein-tyrosine phosphatase of regenerating liver 2), also known as PTP4A2 (Protein tyrosine phosphatase type IVA, member 2), is a member of PTP family and has an important function in controlling cell growth. PRL-2 phosphatases may be multifunctional enzymes with diverse roles in a variety of tissue and cell types. The phosphatase of regenerating liver (PRL) family, comprising PRL-1, PRL-2 and PRL-3, is a group of prenylated phosphatases that are candidate cancer biomarkers and therapeutic targets. PRL-1, PRL-2, and PRL-3 represent a novel class of protein-tyrosine phosphatase with a C-terminal prenylation motif. They are three closely related intracellular enzymes that possess the PTP active site signature sequence CX 5R. The PRL-2 mRNA is elevated in primary breast tumors relative to matched normal tissue, and also dramatically elevated in metastatic lymph nodes compared with primary tumors. PRL-2 plays a role in breast cancer progression. PRL-2 is a pathogenic molecule in hematopoietic malignancies and it has potential as a novel therapeutic target. Post-translational: Farnesylated. Farnesylation is required for membrane targeting and for interaction with RABGGTB. Unfarnesylated forms are redirected to the nucleus and cytosol.

Measured by its ability to cleave a substrate, p-Nitrophenyl phosphate (pNPP). The specific activity is >0.3 pmol/min/μg, as measured under the described conditions.

重组表达

19.9 kDa

N-His

19.4 kDa, under reducing conditions; 19.6 kDa, under non-reducing conditions.

E. coli Accession #: Q12974 | E. coli

<1.0 EU/μg

人(Human)

2-167 aa

MHHHHHHNRPAPVEISYENMRFLITHNPTNATLNKFTEELKKYGVTTLVRVCDATYDKAPVEKEGIHVLDWPFDDGAPPPNQIVDDWLNLLKTKFREEPGCCVAVHCVAGLGRAPVLVALALIECGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRFRDTNGHCCVQ​

No

Yes